Sign in

Private company

Aimmune Therapeutics (United Kingdom)

Aimmune Therapeutics (United Kingdom) is a British pharmaceutical preparations company based in London, founded in 2011.1

Last updated Oct 21, 2026.

Overview

2011Founded1
  • IndustryPharmaceutical Preparations1
  • HeadquartersLondon1
  • Websitewww.aimmune.com
  • Incorporated inDE3
  • Business address8000 Marina Boulevard, Suite 300, Brisbane, Ca 94005-18843
  • Filer categoryLarge accelerated filer3

See how the biggest companies compare on our leaderboards

What it owns

What Aimmune Therapeutics (United Kingdom) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$35.8M4 Dec 31, 2019$29.6M4 Dec 31, 2018+20.9%
Accumulated depreciation$7.2M4 Dec 31, 2019$3.3M4 Dec 31, 2018+120.3%
Property and equipment, net$28.6M4 Dec 31, 2019$26.3M4 Dec 31, 2018+8.6%
Operating-lease assets (leased space)$11.5M4 Dec 31, 2019

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$79.9M4 Dec 31, 2019$107.5M4 Dec 31, 2018−25.7%
Marketable securities, current$63.6M4 Dec 31, 2019$196.4M4 Dec 31, 2018−67.6%
Debt securities available for sale$78.3M4 Dec 31, 2019$196.4M4 Dec 31, 2018−60.1%
Long-term investments$14.7M4 Dec 31, 2019$33.6M5 Dec 31, 2016−56.4%

Leadership

Who has led Aimmune Therapeutics (United Kingdom), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Stephen George Dilly2015–2018
  2. Jayson Donald Alexander Dallas2018–2020

President

  1. Stephen George Dilly2015–2018
  2. Jayson Donald Alexander Dallas2018–2020

Chief financial officer

  1. Warren L. Desouza2015–2017
  2. Eric Bjerkholt2017–2020

Chief operating officer

  1. Howard Raff V.2015
  2. Jeffrey H. Knapp2016–2018
201520202025
Board members and other officers (16)

Former names

  • Allergen Research CorpMar 24, 2015 to Mar 24, 20153

Timeline

  1. Jun 19, 2018New chief executive Jayson Donald Alexander Dallas becomes CEO6
  2. Aug 5, 2015New chief executive Stephen George Dilly becomes CEO7
  3. 2011Founded Founded1

SEC filer profile

How Aimmune Therapeutics (United Kingdom) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAimmune Therapeutics, Inc.2
  • CIK0001631650
  • Employer ID (EIN)45-27482442
  • Filer statusLarge accelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address8000 Marina Boulevard, Suite 300, Brisbane, CA 94005-18842
  • Phone(650) 614-52202
  • Shares outstanding65,450,142 as of Jul 24, 202026
  • Public float$919.7M as of Jun 30, 20194
  • On EDGAR sinceMar 24, 20152
  • Filings425 in all: 4 (181), 8-K (66), 3 (24), SC 13G/A (23), 10-Q (16), SC 13G (11), UPLOAD (8), CORRESP (7)2
    All 41 form types

    SC 14D9/A (7), CT ORDER (6), S-8 (6), S-8 POS (6), 10-K (5), 5 (5), DEF 14A (5), DEFA14A (5), SC 13D/A (5), SC TO-T/A (5), EFFECT (4), D (3), SC 13E3/A (3), 424B5 (2), POS AM (2), S-1/A (2), SC TO-C (2), 15-12B (1), 25-NSE (1), 4/A (1), 424B4 (1), 8-A12B (1), CERTNAS (1), DRS (1), S-1 (1), S-1MEF (1), S-3 (1), S-3ASR (1), SC 13D (1), SC 13E3 (1), SC 14D9 (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Feb 27, 2020
    Quarterly report (10-Q) Jul 30, 2020
    Proxy statement (DEF 14A) Apr 9, 2020
    Latest 8-K (8-K) Oct 19, 2020

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26